Skye Bioscience Inc.(US:SKYE) Globenewswire·2026-01-12 20:29Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly making materially false and misleading statements regarding its business and the effectiveness of its drug nimacimab during the class period from November 4, 2024, to October 3, 2025 [7]. Allegation Details - The lawsuit claims that Skye's management overstated the effectiveness of nimacimab, leading to inflated expectations regarding its clinical, regulatory, and commercial prospects [7]. - Specific allegations include that nimacimab was less effective than represented, and that the public statements made by the defendants were materially false and misleading [7]. Stock Price Impact - Following the announcement of disappointing clinical trial results on October 6, 2025, Skye's stock price dropped by $2.85 per share, or 60%, closing at $1.90 per share [7]. Next Steps for Investors - Investors who purchased Skye securities during the class period and suffered losses are encouraged to contact Bragar Eagel & Squire for more information and to discuss their legal rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is January 16, 2026 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in securities litigation [5]. - The firm has a nationwide practice and handles cases in both federal and state courts [5].